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The characteristic features of sarcomas induced in mice by Moloney murine 
sarcoma virus (MSV-M), 1 namely rapid development and spontaneous regres- 
sion,  have prompted extensive  investigations on humoral and cell  immune 
response in  this  model  (1). A  cause-and-effect correlation between immune 
response and tumor regression can be concluded from observations in immuno- 
logically incompetent hosts. In X-ray-irradiated (2), thymus-deprived (3, 4), or 
congenitally athymic mice (5,  6), Moloney sarcomas always show progressive 
growth.  In immunocompetent mice, the majority of Moloney sarcomas com- 
pletely regress, though few may continue to grow or recur later (7-12).  It has 
been proposed that this recurrence is due to the disappearance of a resistance 
state acquired during tumor regression (10), although the possibility that the 
recurrent tumor may differ from the primary one with respect to, for instance, 
immunosensitivity and]or antigenicity, was not considered. We have therefore 
studied the virological, oncogenic, and antigenic properties of a transplantable 
tumor that reappeared at the site of a  primary regressed Moloney sarcoma. 
Also, two oncogenic cell lines derived from this tumor, and for comparative 
purposes,  ascitic  MSV-M-producing cells  (13) and  a  Moloney helper  virus- 
producing cell line established from these ascitic cells were included in these 
studies. The purpose of this investigation was to obtain information on the 
escape mechanism of tumor cells from immune destruction. 
Materials and Methods 
Animals,  Virus and Cells.  STU-inbred mice,  MSV-M, ascitic MSV-M-producing  cells (asc- 
MSV-M), and its helper-virus-producing  culture derivative (Bc) were the same as those described 
in  preceding studies  (13-15).  MSV-M  was obtained from Flow Laboratories,  Inc.  (Rockville,  Md.; 
code no. MSV-B-62). asc-MSV-M was derived from a weanling mouse that had developed an 
ascitic  tumor after  intramuscular (i.m.)  injection  of  MSV-M; this  ascitic  tumor has since  been 
1  Abbreviations  used  in this paper:  AMC, antibody-mediated cytotexicity; asc-MSV-M, ascitic 
MSV-M-producing cells; Bc, cell line Bc derived from ascitic MSV-M cells; C', complement; CMC, 
cell-mediated cytotoxicity; flu, focus-forming units; [3H]proline-MA, [3H]proline microcytotoxicity 
assay; i.m., intramuscular; i.p., intraperitoneal;  MLV-F, Friend murine leukemia virus; MSV-M, 
Moloney  murine sarcoma  virus; PBS,  phosphate-buffered saline; pfu,  plaque-forming units; 
Sac(-), cell line derived from ascitic cells of secondary tumor; Sac(+), Sac(-) cells infected with 
helper virus (L+-C-type); S+L  +, cells producing focus- and XC plaque-forming  virus; ST, secondary 
tumor. 
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maintained for  more than 4 yr by intraperitoneal  (i.p.)  inoculations  at weekly intervals.  The Bc 
cell  line  was established  from the asc-MSV-M. 
Recurrent Secondary Tumor (ST) and Its Culture Derivatives.  A  5-wk-old STU mouse was 
injected  i.m. with 104 focus-forming units (flu)  in 0.1 ml of a MSV-M-turnor homogenate, and 
developed a palpable tumor 7 days later.  After peak tumor development, regression followed and 
was complete 3 wk later,  as  far  as  could be assessed by palpation. 6 wk ai~r the  regression of  the 
primary MSV-M-induced tumor, a second tumor developed at the same site.  Single cell  suspen- 
sions  for  transplantation were obtained by mincing parts of  the peripheral tumor mass followed 
by filtration  through sterile  gauze.  After washing once in phosphate-buffered  saline (PBS) 
supplemented with antibiotics,  a milky suspension of  cells  was transferred i.m. into  four 4-  to 5- 
wk-old unconditioned STU mice. 2 wk after  transplantation,  tumor development was observed in 
the  recipients.  The tumor has since  been maintained for  more than 2  yr  by serial  parallel  i.m.  and 
i.p.  inoculations  at  intervals  of  2-4  wk in  the  case ofi.m, transplantation,  and at  weekly intervals 
with  the  ascitic  form. A nonproducer cell  line  was established  from  the ascitic  form [Sac(-) cells]. 
Using helper virus released from Bc cells  for  rescue of  a sarcoma virus genome from Sac(-) cells 
(16),  a producer cell  line  of  the sarcoma-helper virus  complex was established [Sac(+) cells]. 
Virus Assays.  Focus and XC plaque assays, [3H]uridine incorporation,  and electron micro- 
scopic  studies  were performed by applying usual  procedures (17-20). 
Light Microscopy.  Cell  monolayers in plastic  Petri dishes were fixed with Bouin's solution 
and stained with hemalum and eesin. 
Determination of Tumorigenicity.  Tumor induction was determined by i.m. inoculation of 
carefully  graded doses of  the various cells  in a 0.1-ml volume into  STU mice of  at least  6 wk of 
age. In addition,  ~  10  s  Bc cells  were inoculated into  newborn mice. The tumorigenic potency of 
supernates from Sac(+) cultures was investigated in adult mice using clarified  cell-free  culture 
fluid  undiluted. Development of  tumors was observed for at least  42 days. In  the case of  Bc cells 
transplanted into  adult mice, the observation period  was extended over  a period of  12 mo. 
Transplantation Protection  Assay.  The ability  of  the various cells  to induce transplantation 
resistance  to  asc-MSV-M, ST, Sac(-), and  Sac(+) cells  was compared by  i.m.  inoculation  of  viable 
asc-MSV-M (105  nuclear cells),  ST (10  s  cells),  Sac(-) (5 × 103  cells),  Sac(+) (5 × 103  cells),  or Bc 
(103  cells)  cells  into  the right  thigh of  STU mice ~ 6 wk of  age. Challenge was performed by i.m. 
inoculation  of  graded doses of  tumor cells  into  the  left  thigh  ~ 2  wk later;  at  this  time asc-MSV-M 
cell-induced  tumors began to regress,  tumors induced by the above-mentioned relatively  small 
number of  Sac(+) cells  also  started to regress or showed deadlock of  tumor growth, and at the 
sites  where ST and Sac(-) cells  had been inoculated,  tumor growth became visible.  In addition, 
mice that had received 106 Bc cells  were challenged 1 yr later  with asc-MSV-M. Age-matched 
mice that had received no primary inoculation were used as controls.  Observation of tumor 
development after  challenge was monitored thrice  weekly for  at  least  40  days; after  inoculation  of 
ST or Sac(-) cells  the observation period was shorter  because of  intercurrent  death of  the  tumor 
bearers.  Amputation of  limbs  bearing  ST  tumors before  challenge in  order to  increase  the survival 
time  was not  successful,  as  fatal  metastatic tumors had already developed. 
Isolation  of  gffector  Cells  and Cytotoxic  Antibodies.  Inoculation of  the above-mentioned cells 
was done by injecting  the desired number of  cells  in a 0.1-ml volume i.m. into  the thigh region of 
mice about 6 wk of  age.  Lymphoid spleen cell  suspensions were prepared 8 and 12 days after  cell 
inoculation  by the method previously described (14,  15).  Pooled spleen cells  of  two or three mice 
were used in  each test.  Blood from  the inoculated  mice was taken at  the days indicated in  Results 
by  puncture of  the  retro-orbital  plexus, and the sera  pooled from at  least  3 animals were stored  at 
-20°C until  use. 
[3H]Proline Microcytotoxicity Assay for the Demonstration of Cell-Mediated Cytotoxicity (CMC) 
and Antibody-Mediated  Cytotoxicity (AMC).  A modification of the [3H]proline microcytotoxicity 
assay ([3H]proline-MA) developed by Bean et al. (21) was used and has been described previously 
(15). The assay measures target cell detachment as an expression of cytotoxicity. In the meantime, 
few minor modifications have been applied. We now prefer the model 48 TC Linbro tissue culture 
plates (Linbro Chemical Co., Inc., New Haven, Conn.). For assay of CMC, 6  x  103 [3H]proline- 
labeled cells in 0.1 ml were added to each well, and for the assay of AMC, the number of cells per 
0.1 ml was 3.5 x  10  ~. Subsequently, the cultures were incubated at 37°C in a 5% CO~ incubator. 
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were added at ratios indicated in Results. After a  42-h incubation, the plates were dipped twice 
into PBS supplemented with 2% fetal calf serum at a  temperature of 37°C.  After trypsinization, 
the cells were  transferred directly  into scintillation vials.  Calculation of percent reduction of 
target cells was performed as described previously (15). 
For determination of AMC, the target cell cultures were incubated for 16-18 h. Then, the cul- 
ture supernates were sucked off using a peristaltic pump (Varioperpex, LKB, Stockholm, Sweden) 
and 0.05 ml of serial threefold dilutions of the sera to be tested were added; after incubation for 1 h 
at 37°C,  0.05 ml of rabbit complement (C') was added. Before use, a rabbit serum was diluted 1:3 
with PBS and then absorbed with agarose (40 mg/ml) for 1 h  at 4°C; after centrifugation at 5,000 
rpm for 20 rain, and filtration through a membrane with a pore size of 45/~m, the serum was used 
at a final dilution of 1:9 or 1:12.  After addition of rabbit C', the cultures were incubated for 2-3 h 
at 37°C  and subsequently harvested for scintillation counting as described above.  Target cells 
treated with either rabbit C' or the serum dilutions to be tested served as controls. Since sera in 
the absence of rabbit C' were without cytotoxicity, evaluation was performed by comparing the 
arithmetic mean of radioactivity of a  group comprising three or four replicates treated with a 
serum dilution and rabbit C' with that of a  corresponding control group to which only rabbit C' 
had been added. The degree of cytotoxic antibody activity is expressed for each serum dilution by 
the percent reduction of target cell radioactivity taking the radioactivity of the control group as 
basis for the calculation of the percent reduction. 
Results 
Virological Properties of the Different Cell Lines.  The virological properties 
of asc-MSV-M cells have been described earlier  (13). Although they produce 
beth sarcoma and helper virus, supernates of a  cell line (Bc cells) originating 
from asc-MSV-M cells produced no foci but plaques in the XC plaque test; 20 h 
aiter the change of the culture medium of confluent cell cultures (5.2  ×  l0  s 
cells/dish), the supernates (4 ml per dish) contained 105 plaque-forming units 
(pfu)/0.2 ml. For ST cells, no indication of oncornavirus release was obtained. 
Suspensions of ST cells derived either from ST tumors or from ascitic ST cells 
were found negative in the XC plaque test and they did not produce foci. Also, 
electron microscopic examinations revealed no  C-type particles.  A  cell  line 
derived from ST cells in their ascitic form, the Sac(-) cell cultures, were found 
free of XC plaque-forming and focus-forming virus. In addition, experiments 
with [aH]uridine,  as well as electron microscopic examinations, gave no evi- 
dence for release of C-type particles from these cells. Also, no p30 antigen could 
be detected in these cells by radioimmunoassay using rabbit anti-p30 Friend 
murine leukemia virus (MLV-F) serum, (kindly performed in the laboratory of 
Dr.  W.  Sch~ifer,  Max  Planck-Institute for  Virus  Research,  Tfibingen,  West 
Germany), and goat anti-gp 69/71 (MLV-F) serum possessed no cytotoxic activ- 
ity against Sac(-)  cells in the  [3H]proline-MA, but it was cytotoxic towards 
Sac(+) cells. The Sac(+) cells were obtained after infection of Sac(-) cells with 
the supernate of the above-mentioned Bc cell line. The release of oncornavirus 
from these Sac(+) cells was demonstrated by the detection of XC plaque- and 
focus-forming virus in the supernate of these cultures (cultures with 6.4 x  105 
cells contained 104 flu/0.2 ml and  105 pfu/0.2 ml),  as well as by [3H]uridine 
incorporation into material banding at a density of 1.16 g/ml. 
Light Microscopy.  The cell line producing focus- and plaque-forming virus 
[Sac(+)  cells],  as well as the sarcoma genome containing nonproducer cells 
[Sac(-) cells] appeared predominantly round or fusiform and refractile. Smooth 
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FIG.  I.  Morphology  of in vitro cell lines. Sac(+)  cells (a) and  Sac(-)  cells (b) appear 
predominantly  fusiform; Bc cells  (c)  differ  by their flattened morphology.  Magnification  × 
340. 
cultures. By contrast, Bc cultures predominantly consisted of flattened, poorly 
refractile cells (Fig. 1). 
Growth  of Tumors  Induced  in  Mice  by  the  Different  Cell  Lines.  Fig.  2 
demonstrates the growth of tumors induced by the cells under study. Tumor 
induction by graded doses of asc-MSV-M  cells has been described previously 
(13). Briefly, i.m. transplantation of these cells usually induces local tumors 
which regularly regress in immunocompotent  hosts. Fig. 2 a shows a represent- 
ative course of tumor development and regression. Deviating from this typical 
course, an asc-MSV-M-induced tumor may sporadically grow progressively or 
may  exhibit  a  biphasic  growth  pattern  (22): after  complete  or  incomplete 
regression, reestablishment of progressive tumor growth occurs and leads to 
death of the host.  In the present studies, the helper virus producing Bc cells 
(Fig. 2 b) never led to local tumors after i.m. inoculation, or to ascitic tumors 
after i.p.  transplantation in adult mice. During an observation period of ~- 12 
mo, white blood changes could not be observed. However, after i.m. inoculation 
of Bc cells into newborn mice, leg enlargement became observable 7-8 wk later, 
and death occurred 8-10 wk after tumor development. Tumor induction after 
i.m. transplantation of graded nonpreducer ST cell concentrations is shown in 
Fig.  2 c.  The time between transplantation  and tumor establishment lasted 
from 1 to ---- 3 wk and depended upon the concentration of the transplants. After 
tumor establishment, ST tumors exhibited a continuous growth pattern and led 
to  the  death  of the  tumor  bearers  between  3  and  7  wk  after  tumor  cell 
transplantation, this interval varying with the transplanted tumor cell concen- 
tration. Transplantation of graded doses of nonproducer Sac(-) cells (Fig. 2 d 
and Table I) caused tumor development between 4 and ~  25 days later, and 
these tumors exhibited a  continuous growth pattern, death of tumor bearers 
occurring between 16 and ~  38 days after cell inoculation. Such tumors showed 
no regression, nor did they show a reduction in tumor size.  Tumors caused by 
inoculation of l0  s Sac(+) cells, a cell line obtained ai~r infection of Sac(-) cells 
with helper virus, grew progressively. The tumors became palpable 4 days after 
cell  inoculation,  and  the  mice  died  about  4-7  wk  after  tumor  induction. 
Inoculation of doses containing 102-104 Sac(+) cells were also followed by the 
development of tumors. Some of these tumors grew progressively, but slower 412  NONPRODUCER  FROM  MOLONEY  SARCOMA  REGRESSOR  MOUSE 
15 
10 
5 
15 
10 
E 
E  S 
U! 
E  15 
-,-.  10 
s 
E  15  ._o 
t-.-,  10 
Asc  -  M SV  -  M 
S*L  *,  R 
a) 
b) 
Bc 
S-L°, 0 
ST 
S* L',  P 
c) 
d) 
5  Sac I - ) 
S*L',  P 
15  ~...-'.  e) 
~)" 
5  o-o- .o- ..... ~-  ..... ~-----o- .......  ~"  Sac N) 
S* L*, PIR 
days  after  tumor  cell  transplantation 
FIG. 2.  Course of tumor development  after i.m.  inoculation  of the various cell strains. 
Two lines for each experiment represent two mice. S-L  +, cells producing only XC plaque- 
forming virus (helper virus); S+L  -, cells carrying the sarcoma genome rescuable by helper 
virus; P, tumor growth without regression;  R, tumor growth followed by regression;  P/R, 
after inoculation  of 108  cells  the  tumor growth  is progressive  without  regression,  but 
inoculation  of about 10' cells results in tumors growing progressively until death of the 
animals, or tumors stop growing  for a variable length of time and either start to grow 
again or regress; O, no tumor development in adult mice. (e), after inoculation  of 10  e cells/ 
mouse; (©), after inoculation of 10  * cells/mouse. Number at the end of a curve indicates the 
day of  death after  inoculation.  Diameters of  tumors were determined using  a caliper. 
than after inoculation of 106 cells; others stopped growing for a  variable length 
of time and either started then with a steady continuous growth until the death 
of the  animals,  or regressed  (Fig.  2 e  and  Table  I).  These growth  patterns  of 
Sac(+) cells may be explained in the case of continuous growth by the selection 
of nonproducer cells,  for example cells with properties of ST cells, or immuno- 
resistant  cells.  Results  of the  following experiments,  however,  do not support 
these conceptions:  a  tumor was  induced by i.m.  inoculation  of 5  ×  104 Sac(+) 
cells  in  the  right  thigh  of a  mouse.  5  days  later,  this  mouse  was  protected 
against a challenge with 5  ×  104 Sac(+) cells in the left thigh. The tumor on the 
right thigh reached a diameter of 1.1 cm on the 20th day ai~r inoculation and it 
was then removed for the preparation of a cell suspension. As early as 72 h  after 
the  start  of  the  focus  assay,  focus  development  was  observed  up  to  cell E.  WEILAND,  M.  MUSSGAY,  AND  F.  WEILAND 
TABLE  I 
Cross Transplantation Immunity* 
413 
Types and number of cells used for challenge 
Calls used for 
primary inoc-  Groups  ofmice~  asc-MSV-M  ST  Sac (-)  Sac (+) 
ulation$ 
10  e  101  104  1(?  105  104  1~  10'  10  a  10  ~  10  e  10  s  104  10  ~  102 
ase-MSV-M  Ino.  1/~'  0/5  0/5  515  2/5  0/5  5/5  5/6  2/6  0/5  3/5  2/6 
(S+L*,R)  (13)  (14-20)  (20-22)  (6)  (8-20)  (11-16)  (<5-9)  (7-12) 
C  5/5  5/5  5/5  5/5  4/5  2/6  6/6  6/6  4/6 
(5)  (5)  (5)  (8)  (11-18)  (18-20)  (4-6)  (8-18)  (11-13) 
ST  Ino. 
(S*L-, P) 
C 
Sac(-)  Ino. 
(S*L-, P) 
C 
Sac(+)  Ino. 
(S+L-, P/R) 
C 
Bc  Ino. 
(S-L*, O) 
C 
5/5  4/4  5/5  5/5  3/4  ¶ 
(6)  (6)  (6-8)  (8)  (14-32) 
5/5  5/5  5/5  5/5  4/5  2/5 
(6)  (6)  (6)  (8)  (11-18)  (18-20) 
0/6  0/2 
1/6  4/4  5/5  5/5  5/5 
(13)  (<5)  (<5)  (<5-7)  (<5-9) 
5P  5P  5P  5P 
12/12  9/11  ¶  I  5/5  4/5  3/5 
(7)  (11-18)  (7-12)  (7-9)  (9) 
8/8  11/11  1O/ll  6/12  5/5  4/5  3/6 
(7)  (11-16)  (11-26)  (14-21)  (<5-7)  (7-9)  (9-12) 
4P/1R  2P/2R  3R 
0/5"*  0/5"*  4/4  4/6  0/6  0/6  4/5  2/6  0/5  0/5 
(6-8)  (12-16)  (5-7)  (9, 14) 
5/5  5/5  4/4  4/5  6/6  1/6  4/4  5/5  5/5  4/5 
(3-6)  (6)  (6)  (8-14)  (12-19)  (12)  (<5)  (<5)  (<5-7)  (7-9) 
4P  5P  4P/1R  2P/2R 
0/5  0/5  0/5  5/5  3/5  1/5  6/6  5/6  5/6  4/6  5/5  0/5  0/5  0/5 
(8-11)  (14)  (22)  (4-8)  (5-15)  (13-21)  (13-19)  (5-7) 
5/5  5/5  5/5  5/5  4/5  2/5  6/6  5/6  4/6  1/6  4/4  5/5  5/5  4/5 
(6)  (6)  (6)  (8)  (11-18)  (18-20)  (4-8)  (5-13)  (13-15)  (15)  (<5)  (<5)  (<5-7)  (7-9) 
* Primary inoculation of cells was done i.m. into the right thigh of 6-wk-uld mice; ~- 2 wk later, i.m. challenge inoculation into the left thigh was 
performed. 
$ See legend of Fig. 2. 
§ Ino., groups of mice with primary cell inoculation; C, control groups. 
II Number of mice with tumors/number of inoculated mice; number in parentheses indicates the day after challenge at which a tumor was palpable. 
¶ Intercurront death due to the primary tumor. 
** 5 x  10  s and 5 x  104 cells were used for challenge. 
concentrations  of 102 nuclear cells/0.2 ml,  thus indicating  the presence of flu- 
releasing cells,  since formation of foci induced by the division of transformed 
nonproducing cells would require  more time.  Moreover, the foci reacted posi- 
tively in the XC plaque assay performed 6 days after the beginning of the test. 
Simultaneously,  the tumor cell suspension was transplanted  i.m.  into normal 
mice  and  into  mice that  had  received Sac(+)  culture  supernate  i.m.  11  days 
before. Doses containing  106 nuclear cells and a  3-, 9-, and 27-fold dilution of it 
were used. Each group of mice consisted of 5-6 animals.  18 of the 20 mice of the 
four control groups developed tumors with a progressive (12 cases) or regressive 
(6 cases) course, whereas no tumor was palpable in the 22 mice pretreated with 
Sac(+) virus. 
After we had obtained the results described above, the virological and growth 
properties of the different cell strains were designated in the tables and figures 
as indicated in the legend of Fig. 2. 414  NONPRODUCER  FROM  MOLONEY  SARCOMA  REGRESSOR  MOUSE 
Growth  of Tumors  Caused  by  Virus  Released  from  Sac(+)  Cells.  The 
observation  that  the  sarcoma-helper virus  complex-producing Sac(+)  cells 
induced in many cases progressively growing tumors without regression and 
also produce focus- and XC plaque-forming virus, prompted us to study whether 
this virus causes tumor development with growth characteristics similar to that 
induced by the cells releasing this virus. Intramuscular inoculation of super- 
nates from Sac(+) cells containing 104 flu]0.1 ml was followed by leg enlarge- 
ment in 25 of 36 mice which was palpable between 6 and 12 days after virus 
inoculation. The tumors regressed completely in all cases ~3 wk after virus 
inoculation. None of the regressed tumors reappeared during an observation 
period of ---2 mo after regression was complete. 
Induction of Cross Transplantation Resistance.  To study the capacity of the 
different cell  lines  to  induce  homologous  and  heterologous transplantation 
immunity, cross tests were performed. Table I summarizes the results. It can be 
seen that after application of cells releasing either XC  plaque-forming virus 
(i.e.,  Bc cells)  or both focus-  and XC plaque-forming virus [i.e.,  asc-MSV-M, 
and  Sac(+)  cells]  a  transplantation resistance existed against the  sarcoma- 
helper virus-producing cells. After application of the helper virus-producing Bc 
cells, this resistance was complete against three concentrations of asc-MSV-M 
cells and strong against Sac(+) cells, i.e. against cells producing the sarcoma- 
helper virus complex. Even 1 yr after Bc cell inoculation, complete transplan- 
tation resistance existed against a challenge with l0  s, 105, and 104, respectively, 
asc-MSV-M  cells.  After inoculation of asc-MSV-M  and Sac(+) cells, a  strong 
transplantation immunity was induced against asc-MSV-M  cells.  Resistance 
against Sac(+) cells was somewhat less; 105 Sac(+) cells were not rejected in all 
mice challenged with this cell concentration. On the other hand, transplanta- 
tion of the helper virus-producing cells (Bc) resulted in no resistance against 
the  nonproducer cells  [ST  and  Sac(-)  cells]  and  inoculation with  sarcoma- 
helper virus complex-producing cells  [asc-MSV-M  and Sac(+) cells] was fol- 
lowed by only very weak resistance against these nonproducer cells.  These 
nonproducer cells also failed to  induce transplantation resistance under the 
conditions tested.  The nonproducer ST  cells did not  induce transplantation 
resistance  against  asc-MSV-M  cells,  and  when inoculated into  ST  cell-pre- 
treated mice they were also not rejected, but the group receiving the lowest 
challenge  concentration could  not  be  observed  during  the  whole  required 
observation period because of intercurrent death of the challenged animals. The 
results obtained with the in vitro cultured nonproducer Sac(-) cells resembled 
those observed with the nonproducer ST cells.  The nonproducer Sac(-) cells 
neither induced transplantation immunity against producer cells [102 Sac(+) 
cells], nor against Sac(-) cell inocula containing 105 and 104 cells.  As with the 
nonproducer ST  cells,  it  could not be  decided whether or not  the  cultured 
nonpreducer Sac(-) cells induced protection against challenge with lower cell 
concentration because Sac(-) tumor bearers died during the latency period of 
tumors when using relatively small numbers of Sac(-) cells as challenge. 
Comparison  of Cultured  Cell  Lines  as  Target  Cells  in  CMC  and  AMC 
Assays.  Experiments were performed to determine whether or not differences 
exist between the three cultured cell lines with regard to their sensitivity as E.  WEILAND,  M.  MUSSGAY,  AND  F.  WEILAND 
TABLE  II 
Comparison of Three Cell Lines Derived from MSV-M-Induced 
Tumors as Target Cells in a CMC Assay 
Target cells 
Lymphoid spleen cells  from Sac(+) (S+L  +,  P/R) 
tumor bearers (12  days after  inoculation) 
Spleen cell:target cell ratio 
250:1  125:1  62.5:1 
Bc 
(S-L  +,  O) 
% 
79*  78  70 
Sac(+) 
28  19  0  (S+L  +, P/R) 
Sac(-) 
175  0  n.t.§  (S+L  -,  P) 
"5 Percent reduction of  target cell  radioactivity;  values are significant 
by the Student's t  test  at  P < 0.001  with the exception of  5,  where P 
<  0.05. 
§ n.t,, not tested. 
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TABLE  HI 
Comparison of Three Cell Lines Derived from MSV-M-Induced Tumors as Target Cells 
in an AMC Assay 
Target cells 
Pooled sera from mice inoculated with 
Sac(+) cells  (S+L  +,  P/R)* 
Serum dilutions 
Pooled sera from mice inoculated 
with Bc cells  (S-L  +,  0)5 
Serum dilutions 
1:27  1:81  1:243  1:729  1:2,100  1:27  1:81  1:243  1:729  1:2,100 
Bc 
(S-L  +, O) 
Sac(+) 
(S+L +, P/R) 
Sac(-) 
(S+L  -, P) 
% 
74§  75  62  51  14  36  46  41  23  0 
P  <0.05 
96  96  93  81  53  75  83  69  33  0 
76  61  45  30  n.t.II  0  0  0  0  n.t. 
P  <0.01  P<0.01 
* Serum was taken 41 days after cell inoculation. 
5 Serum obtained 147 days after cell inoculation. 
§ Percent reduction of target cell radioactivity, P  =  <0.001 with exceptions indicated in the table. 
II n.t., not tested. 
target cells in the [3H]proline-MA applied for the demonstration of CMC and 
AMC. 
Lymphoid spleen cells were prepared from mice that had been i.m. inoculated 
with 10  4 sarcoma-helper virus-producing Sac(+) cells 12 days before, and that 
had become tumor bearers. A lymphoid spleen cell preparation from uninocu- 416  NONPRODUCER  FROM  MOLONEY  SARCOMA  REGRESSOR  MOUSE 
lated age-matched mice served as control. The Sac(+) cells, the helper virus- 
producing Bc cells, and the nonproducer Sac(-) cells were used simultaneously 
as target cells in the [3H]proline-MA. Table II summarizes the results. It can be 
seen that effector cells exhibited the strongest cytotoxic activity towards the 
helper virus-releasing Bc cells; a spleen cell:target cell ratio of 250:1 resulted in 
a  target  cell  reduction of 79%. At  this  ratio,  the  percent  reduction of the 
sarcoma-helper virus complex-producing  Sac(+) cells was only 28%, and that of 
the nonproducer Sac(-) cells, 17%. At spleen cell:target cell ratios of 125:1 and 
62.5:1, the difference in sensitivity to effector cell activity was very pronounced 
between Bc cells on one side and the Sac(+) cells and Sac(-) cells on the other. 
Next, the three cultured cell lines were used as target cells for the demonstra- 
tion of C'-dependent AMC in the [3H]proline assay. The results of  representative 
experiments are  shown in  Table  III.  Sera  from three  mice bearing tumors 
induced by Sac(+) cells were obtained and pooled 41 days after inoculation of 
1.8 × 104 cells. This serum pool possessed cytotoxic antibodies against the helper 
virus-releasing Bc cells and the Sac(+) cells, and also against the nonproducer 
Sac(-) cells. Pooled sera taken from five mice inoculated with nontumorigenic 
Bc cells 147 days ai~r inoculation were cytotoxic only against the two producer 
cells,  but  not  toward  the  nonproducer cell  line.  In  beth  experiments,  the 
sarcoma-helper virus-producing Sac(+) cells were the most sensitive target cell 
for detection of AMC. 
Induction of CMC and AMC by the Different  Cell Lines.  Induction of CMC 
was studied after application of the helper virus-producing Bc cells, the two 
sarcoma-helper virus complex-producing  cells [ascitic MSV-M cells, and Sac(+) 
cells], and the nonproducer Sac(-) cells, respectively. 12 days ai~r inoculation, 
spleen cells from the inoculated mice were prepared and tested for cytotoxicity 
in the [SH]proline-MA. The helper virus-releasing Bc cells served as target cells 
because they had been shown to be the most sensitive cells for the detection of 
cytotoxic  effector  cells  as  outlined above.  As  can  be  seen  from  Fig.  3,  all 
producer cells induced a relatively strong CMC, the helper virus-producing cells 
being somewhat less effective than the two cell lines releasing the sarcoma- 
helper  virus  complex  (S+L ÷  cells).  It  should  be  noted  that  there  was  no 
significant difference between the regressor S+L  + cells (asc-MSV-M cells) and 
the S+L  ÷ cells, growing frequently progressively [Sac(+) cells], and also that 
the  nonproducer Sac(-)  cells  induced no detectable  CMC.  In an  additional 
experiment, mice were inoculated with the nonproducer Sac(-) cells and spleen 
cells were prepared between  1  and  ---4 wk after  inoculation.  None  of these 
preparations possessed a cytotoxic activity against the helper virus-producing 
Bc cells; in this experiment the producer Sac(+) and the nonproducer Sac(-) 
cells were in addition used as target cells, and no cytotoxic reaction could be 
detected with either one. 
The four cell lines were also tested for their capacity to induce AMC. Mice 
were inoculated with 106 helper virus-producing Bc cells, 106 asc-MSV-M cells 
(S+L+), 104 Sac(+) cells (S+L+), and 104 nonproducer Sac(-) cells, respectively, 
and bled 25 days later. The collected sera of each group were examined for the 
presence of C'-dependent cytotoxic antibodies in the [3H]proline-MA using Bc 
cells as target cells.  Percent reduction of target cell radioactivity caused by E.  WEILAND,  M.  MUSSGAY,  AND  F.  WEILAND  417 
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FIG.  3.  Comparison of  the cytotoxic  activity  of  spleen cells  obtained from mice inoculated 
with cells  from one of  the four cell  lines.  Each mouse received 106 cells,  and spleen cells 
were prepared 12 days after  inoculation.  With the exception of  Bc cell  (S-L  +,  O)-inoculated 
mice, all spleen cell  donors were tumor bearers. CMC  was determined in the [3H]proline- 
MA  using Bc cells (S-L  +, O) as target cells.  Percent reduction values of target cell 
radioactivity  are significant  by the Student's  t  test  at  P  < 0.001. (O- - -O), no reduction of 
target  cell  radioactivity. 
serum obtained from mice inoculated  with Bc cells  and diluted  1:81  was 23%. 
The corresponding values for  sera  from mice that had received  cells  of  the two 
lines  producing  the sarcoma-helper virus  complex were 25% (Sac(+) cells)  and 
43% (asc-MSV-M cells),  whereas 1:9  diluted  serum collected  from mice inocu- 
lated  with  the  nonproducer  Sac(-)  cells  possessed  no  demonstrable  cytotoxic  ac- 
tivity.  These results  indicate  that the producer cells  induce the development of 
cytotoxic  antibodies  regardless  of  whether they are nontumorigenic, regressor, 
or  prevalently  progressor  cells.  No cytotoxic  antibodies  against  the  helper  virus- 
producing Bc cells,  the sarcoma-helper virus  complex-releasing Sac(+) cells, 
and  the  nonproducer  Sac(-)  cells  could  be  detected  in  sera  from  mice  inoculated 
with  the nonproducer Sac(-) cells  demonstrated above to  be a sensitive  target 
cell  for  cytotoxic  antibodies  induced  by  Sac(+)  cells  (S+L+). 
Tumor  Growth  after  Simultaneous  Inoculation  of Producer  Cells  (S+L +) 
Differing  in  Their Oncogenic Potency  into the Same Mouse.  The frequently 
progressive  growth of Sac(+)  cell  tumors,  in  spite  of the  strong capacity  of 
Sac(+) cells to induce transplantation immunity, CMC, and AMC, prompted us 418  NONPRODUCER  FROM  MOLONEY  SARCOMA  REGRESSOR  MOUSE 
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Fro.  4.  Simultaneous  inoculation  of Sac(+)  cells  (S+L +,  P/R)  and  ascitic  MSV-M cells 
(S+L  +, R) into the same mouse. Each group consists of 10-12 animals of both sexes; the mice 
were inoculated at the age of about 7 wk. Group I: inoculation of 10  6 nuclear ascitic MSV-M 
cells (S+L ÷, R)/mouse i.m. into the left thigh.  Group II: 5 ×  10  4 Sac(+) cells (S+L  +, P/R) into 
the right thigh.  Group III: 10  8 ascitic MSV-M cells (S+L  ÷, R) into the left thigh and 5  x  10  4 
Sac(+) cells (S+L  +, P/R) into the right thigh.  Group IV: a  mixture consisting of 10  6 ascitic 
MSV-M  cells  (S+L  +,  R)  and 5  ×  10  4 Sac(+)  cells  (S+L  +,  P/R)  in  the  left  thigh.  Tumor 
development was monitored three times weekly by measuring the tumor diameter using a 
caliper. 
to study  whether or not there  is  an  indication  for the  presence  of blocking 
factors which protect the tumor cells in vivo from anti-tumor immune responses. 
Therefore, we performed an experiment in which Sac(+) cells and asc-MSV-M 
cells (the latter also producing the sarcoma-helper virus complex but inducing 
regressing  tumors)were  inoculated  in  a  group  of mice  simultaneously  at 
separate  sites  ofa mouse to see  whether or not development of Sac(+)  cell 
tumors prevent the regression of tumors induced by asc-MSV-M cells.  Fig.  4 
(group  III)  shows  that  under  such  circumstances,  regression  of the  tumors 
induced by asc-MSV-M cells occurred in a course comparable with that of the 
control group (group I). The tumor appearing at the site where Sac(+) cells had 
been inoculated also had a growth pattern like that of the corresponding control 
group  (group  II).  In both  groups  II  and III,  the Sac(+)  tumors grew rather 
slowly but progressively;  no regression was observed.  After inoculation of a 
mixture  of asc-MSV-M  cells  with  Sac(+)  cells  into  the  left  thigh,  tumors 
appeared  with  the  growth  properties of Sac(+)  tumors,  but with  a  slightly 
enhanced development in comparison with the tumors which had been induced 
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Discussion 
According to Ribacchi (10), the recurrence of MSV-M  tumors supports the 
hypothesis that the resistance state acquired during regression is a transient 
condition. However, recurrence may also be explained by the conception that 
transformed cells differing in particular properties from tumor cells eliminated 
by immune mechanisms can escape the immune response of the host.  Such 
properties are, for example, growth behavior, antigenicity, and/or immunore- 
sistance. To our knowledge there is no report on the properties of a recurrent 
tumor with regard to its virological and immunological properties. Therefore, 
in the present studies we attempted to characterize cells of a secondary tumor 
appearing in a  Moloney regressor mouse at the site of a  primarily regressed 
MSV-M induced tumor; cell strains derived from these tumor cells, as well as 
ascitic MSV-M cells inducing regressing tumors and a helper virus-preducing 
cell line  derived from these  ascitic cells,  were included for comparison.  No 
evidence for the release of C-type particles from the cells of the ST was obtained, 
but rescuable sarcoma virus genome could be demonstrated in the ascitic form 
of the ST tumor as well as in its culture derivative, Sac(-) cell line. These 
nonproducer Sac(-)  cells  induce tumors which grow without  regression in 
immunecompetent adult mice. As in the nonproducer mouse line derived from 
in vitro MSV-M-transformed BALB/3T3 cells (16), no evidence for viral antigen 
was obtained.  Neither the presence of MuLV group-specific p30  nor gp69/71 
could  be  detected  in  Sac(-)  cells.  However,  no  comparison  between  the 
nonproducer BALB/3T3 and our Sac(-) cells with regard to tumorigenicity can 
be  made,  since the  nonpreducer cells of Aaronson and Rowe  (16) had been 
inoculated into irradiated mice. 
The antigenicity of transformed nonproducer murine cells is not regularly 
demonstrable, and has to be considered to be weak since repeated immuniza- 
tions  are  necessary  to  induce  a  demonstrable  immune  response  (23). No 
immunogenicity  of MSV-transformed nonproducer cells was detected by Strouk 
et al.  (24), and Stephenson and Aaronson (25), and the failure in the present 
study of ST  and Sac(-) cells to  induce an  immune response supports these 
observations.  The progressive growth of tumors induced by the nonproducer 
Sac(-) cells can be explained by their poor antigenicity. A suppression of an 
immune response in ST tumor-bearers against MSV-M producer tumors could 
not be deflected in a preceding study (26). 
The Sac(+) cells obtained after infection of the nonproducer Sac(-) cells with 
helper virus were shown to release focus- and XC plaque-forming virus, and to 
possess a strong antigenicity. Despite their capacity to induce transplantation 
immunity, C  MC, and AMC, tumors induced by the Sac(+) cells frequently grew 
progressively. This frequent progressive growth of tumors induced by Sac(+) 
cells, despite an ongoing anti-tumor immune response, cannot be explained by 
antigenic modulation of tumor-associated antigens or immunological enhance- 
ment, since we observed rejection of tumor transplants in preimmunized mice. 
Inhibition of CMC  by serum blocking factors and immunosuppression of the 
host's immune response seems also not to be operative as demonstrated by the 
regression of asc-MSV-M  (S+L+)-induced tumors in mice simultaneously inocu- 
lated with Sac(+) cells (S÷L*), which became bearers of progressively growing 
Sac(+)-tumors. 420  NONPRODUCER  FROM  MOLONEY  SARCOMA  REGRESSOR  MOUSE 
Failure to induce demonstrable transplantation  immunity,  CMC, and AMC 
was not accompanied with failure to react with products of an immune response 
against cells producing the sarcoma-helper virus complex as demonstrated with 
the Sac(-) cells. These nonproducer Sac(-) cells reacted as target cells for the 
demonstration of antibody-mediated cytotoxicity, and to a small extent as target 
cells for the demonstration  of cell-mediated cytotoxicity. The properties of the 
component of the nonproducer  Sac(-)  cells reacting with Sac(+)  cell-induced 
cytotoxic antibodies remain to be determined;  it may represent  a  transforma- 
tion-specific surface antigen. 
The observation that the sarcoma-helper virus complex-releasing Sac(+) cells 
and the helper virus-producing Bc cells, both producing the same helper virus, 
differ in  their  reactivity against  cytotoxic effector cells induced  by sarcoma- 
helper virus complex-producing cells is of considerable interest.  The  relative 
insensitivity of Sac(+) cells is not mediated by components released from these 
cells since addition of Sac(+) cells to Bc cells did not decrease the sensitivity of 
the latter (result not shown). The difference in sensitivity between Bc cells and 
Sac(+) cells in CMC may be due to a  smaller amount of helper virus produced 
per  Sac(+)  cell  in  comparison  to  Bc  cells.  However,  this  difference  in  the 
amount of helper virus production is without influence on the sensitivity of the 
two  cells  in  the  AMC  assay.  Furthermore,  in  view of the  difference  in  the 
morphological phenotype between Sac(+) and Bc cells, it would be interesting 
to study whether or not the insensitivity of Sac(+) cells for CMC in contrast to 
AMC is due to the reduction of cytoskeletal elements that seems to be correlated 
with the phenotype in oncornavirus-transformed  cells (27, 28). Such a decrease 
in  number  and  distribution  of cytoplasmic  microfilaments  may result  in  an 
interference with steps in the lytic process in CMC  (29,  30).  Besides this,  one 
may consider that H-2 restriction exists in CMC in the MSV-M mouse system 
(31), and one can speculate that differences in the expression of H-2 between the 
two cell lines are responsible for their different reactivity against effector cells. 
The presented results stress the importance of the cell type used as target cell 
for the detection of CMC. Contradictory results reported on the demonstration 
of cytotoxic effector cells in mice with Moloney sarcoma  (for review see Levy 
and Leclerc, 1) can be explained by the use of target cells differing in sensitivity. 
The described relative insensitivity of Sac(+) cells  (S+L  +) against cytotoxic 
effector cells, and possibly a growth behaviour which protects tumor cells within 
the  tumor  mass  from  immune  attack  may  be  responsible  for  the  escape  of 
Sac(+)  tumors  from  immune  surveillance.  The  transplantation  resistance  of 
mice preimmunized  with producer cells against  a  challenge with Sac(+) cells 
may be explained with the assumption that mice that have already mounted a 
strong CMC and AMC response are able to reject a relatively small number of 
Sac(+) cells.  The observation that the sarcoma-helper virus complex released 
from Sac(+) cells induced tumors which regress,  makes it difficult to assume 
that the escape of Sac(+) cell-induced tumors from immune destruction is the 
result of at least some fraction of newly infected cells becoming nonproducer, 
particularly in the presence of antibodies which neutralized helper virus. This 
observation makes it more reasonable to assume that the progressive growth of 
tumors induced by the producer cell line derived from ST cells is a  property of 
these transformed cells per se. Such a property, together with a poor antigenic- E.  WEILAND,  M.  MUSSGAY,  AND  F.  WEILAND  421 
ity, may also allow the nonproducer Sac(-) cells to escape from immune surveil- 
lance. 
Summary 
Cells from a  secondary tumor developing at the site of a regressed Moloney 
sarcoma virus-induced tumor could be passaged in adult STU mice by intramus- 
cular and intraperitoneal inoculation. The tumors induced by these cells,  as 
well as by a cell line derived from it, grew progressively and led to death of the 
animals between  3  and  7  wk  after tumor transplantation.  No  evidence for 
production of virus from these cells was obtained or for the presence of viral 
antigens (p30,  gp69/71).  From both cell variants, sarcoma virus genome could 
be rescued by infection with helper virus, resulting in the establishment of a 
cell line producing focus- and XC plaque-forming virus. The rescued producer 
cells very frequently also produced tumors which finally grew progressively. 
The nonproducer cells were not immunogenic, as was demonstrated in cross 
transplantation tests and in studies for cell-mediated cytotoxicity (CMC) and 
complement-dependent antibody-mediated cytotoxicity (AMC).  The  producer 
cells,  however, were  demonstrated to possess a  strong immunogenicity. The 
nonproducer cells, though nonimmunogenic, revealed a weak immunosensitiv- 
ity when used for challenge in the transplantation protection assay or as target 
cell  for the  demonstration of AMC  and  CMC,  if the  immune response  was 
induced by cells producing the sarcoma-helper virus complex, but not by cells 
producing only helper virus.  The nonproducer cells,  as well as their rescued 
producer derivative, showed a stronger reactivity with cytotoxic antibodies than 
with cytotoxic cells, whereas the helper virus-producing cell line was compara- 
bly suitable as target cell for AMC and CMC.  The recurrence of a  regressed 
Moloney sarcoma is assumed to be the result of the occurrence of transformed 
nonproducer cells escaping immune destruction, and not as a consequence of a 
depleted immune resistance in the host. 
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